Robenacoxib-d5

Robenacoxib-d5 is a deuterated form of the nonsteroidal anti-inflammatory drug (NSAID), robenacoxib. It is commonly used in veterinary medicine for the treatment of pain and inflammation associated with osteoarthritis and postoperative pain in dogs and cats. Chemically, robenacoxib-d5 is a selective inhibitor of cyclooxygenase-2 (COX-2), an enzyme involved in the production of prostaglandins that cause pain and inflammation. By inhibiting COX-2, robenacoxib-d5 reduces pain and inflammation without affecting the production of prostaglandins involved in normal physiological processes. Robenacoxib-d5 is administered orally in tablet form and is rapidly absorbed into the bloodstream, with peak plasma concentrations reached within 1-2 hours. It has a half-life of approximately 4 hours in dogs and 2.5 hours in cats. As with all NSAIDs, robenacoxib-d5 carries a risk of adverse effects, particularly gastrointestinal ulceration and bleeding, as well as renal and hepatic toxicity. It should not be used in animals with a history of sensitivity to NSAIDs, or those with pre-existing renal or hepatic disease. Careful monitoring is recommended during treatment with robenacoxib-d5, and it should only be used under the guidance of a licensed veterinarian.